Bioatla LLC, of San Diego, said Global BIO Impact Fund, a U.S.-based bioscience investment fund, committed to invest $45 million, including $15 million in Bioatla equity by the end of January and $30 million by the end of March in direct funding for the early development of several conditionally active biologic, or CAB, antibody therapeutics. Through the program funding, Global BIO will share in the risks and the potential returns of Bioatla's first four CAB candidates that receive investigational new drug application approval by the FDA. The specific CAB candidates under agreement would be at Bioatla's decision and could include CAB products in development under the firm's May 2015 collaboration with Beijing Sinobioway Group Co. Ltd., of Beijing. (See BioWorld Today, June 12, 2015.)

Cardiorentis AG, of Zug, Switzerland, said it raised CHF60 million (US$60 million) in a series B financing. Led by three new private investors, the equity financing will support the commercial buildout of ularitide, the company's phase III treatment for acute decompensated heart failure, including upcoming regulatory submissions expected in the second half of 2016.

Clearside Biomedical Inc., of Alpharetta, Ga., said it filed an S-1 with the SEC related to a proposed IPO. The shares to be offered and price range have not yet been determined. Clearside, which develops drugs to treat blinding diseases of the eye, plans to list its stock under the ticker CLSD. RBC Capital Markets and Stifel will serve as joint book-running managers, while Needham & Co. and Wedbush Pacgrow Healthcare will serve as co-managers.

Iconic Therapeutics Inc., of South San Francisco, said it closed a $40 million series C round. Proceeds will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication. The round included new investors HBM Healthcare Investments, Cormorant Asset Management, and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeckfund Ventures participated in the capital raise.

OWC Pharmaceutical Research Corp., of Petach Tikva, Israel, said it entered a $750,000 equity purchase agreement with Kodiak Capital Group LLC. Under the terms, OWC has the right to sell Kodiak $750,000 of OWC's common stock. Proceeds will be utilized by OWC to further develop the company's cannabis-centric products and for working capital.